Blood
Articles in this Issue
Safety and efficacy of selinexor sequential azacytidine in newly diagnosed patients with myelodysplastic syndromes EB1 or EB2: A single-center, single-arm, phase ib/II trial
Abstract Background: Higher-risk MDS (HR-MDS), defined by the Revised International Prognostic Scoring System (IPSS-R) as intermediate, high...
Sirolimus plus low-exposure calcineurin inhibitors as an alternative gvhd prophylaxis in CNI-intolerant recipients: A retrospective study
Abstract Introduction: Graft-versus-host disease (GvHD) remains a major obstacle to long-term survival after allogeneic hematopoietic stem c...
Prognostic and therapeutic impact of FLT3 mutations and allelic burden in myelodysplastic syndromes and chronic myelomonocytic leukemia: Results from a multicenter cohort study
Abstract Background: While mutations in the fms-like tyrosine kinase 3 (FLT3) gene are well-established adverse drivers in acute myeloid leu...
Chronic myeloid leukemia and ASXL1 mutations: A distinct entity requiring special attention
Abstract Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm characterized by the t(9;22) translocation, which results in the BC...
Impact of COVID-19 infection on hospitalization outcomes in patients with myeloproliferative neoplasms: Analysis of the national inpatient sample 2020–2021
Abstract INTRODUCTION: Myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic stem cell disorders characterized by overprodu...
Morphologic leukemia-free state (MLFS) is associated with inferior outcomes in patients with Acute Myeloid Leukemia (AML) treated with front-line azacitidine plus venetoclax
Abstract Background: Azacitidine plus venetoclax (Aza-Ven) is now standard of care for newly diagnosed acute myeloid leukemia (AML) in patien...
Treatment of Acute Myeloid Leukemia patients over the age of 80 with venetoclax and azacitidine
Abstract Introduction: Octogenarians and Nonagenarians diagnosed with acute myeloid leukemia (AML) are frequently exclud...
Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial
Abstract Background: Richter transformation (RT) represents transformation of chronic lymphocytic leukemia (CLL) to an aggressive lymphoma h...
Real-world evidence evaluation of the safety and efficacy of intensive chemotherapy with or without gemtuzumab ozogamicin (GO) in patients with newly diagnosed Acute Myeloid Leukemia (AML) and favorable or intermediate risk cytogenetics
Abstract Introduction Gemtuzumab ozogamicin (GO) is approved for use in combination with cytarabine plus daunorubicin (7+3) for the treatmen...
Impact of c-KIT and FLT3 mutations on survival outcomes in core-binding factor acute myeloid leukemia: A systematic review and meta-analysis
Abstract Background: Core-binding factor acute myeloid leukemia (CBF-AML) is generally considered a favorable-risk subtype; however, prognos...
Efficacy and safety of chimeric antigen receptor (CAR) T-cell therapy in richter transformation: A systematic review and meta-analysis
Abstract Introduction: Richter transformation (RT) is an aggressive transformation of chronic lymphocytic leukemia (CLL)...
Real-world outcomes of extended reduced-dose apixaban versus full-dose apixaban in cancer-associated venous thromboembolism
Abstract Introduction Venous thromboembolism (VTE) remains a significant cause of morbidity and mortality among patients with active cancer....
Long-term mitapivat treatment improves inflammatory pro-fibrotic cardiomyopathy in a murine model of β-thalassemia.
Abstract Hypertrophic cardiomyopathy (HC) is a severe invalidating complication of ß–thalassemia (ß–thal), contributing to reduced patients'...
Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib
Abstract Introduction Gecacitinib (GCA), a JAK and ACVR1 dual inhibitor, demonstrated spleen, symptom, and anemia benefits in myelofibrosis...
Circulating tumor cells (CTCs) combined with frailty index offer an improved stratification system for transplant-ineligible newly diagnosed multiple myeloma patients
Abstract Background Higher levels of circulating tumor cells (CTCs) have recently emerged as a negative independent prognostic factor in tra...
Phase 1 study of GCC2005, an allogeneic CD5-directed CAR-NK therapy, for patients with Relapsed/Refractory NK/T-cell malignancies
Abstract Introduction/Background Relapsed or refractory (R/R) NK and T-cell malignancies remain an area of high unmet need, with limited tre...
Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations
Abstract Objective Bleximenib is a potent, selective menin inhibitor with activity in NPM1-mutated (NPM1m)or KMT2A-rearranged (KMT2Ar) acute...
Redefining early vs late progressive disease (PD) in chronic lymphocytic leukemia: A pooled analysis of fixed-duration therapies
Abstract Background: Progression-free survival (PFS) is strongly correlated with overall survival (OS) after time-limited first-line treatme...
Prognostic impact of TP53 mutation status and variant allele frequency in myelodysplastic syndromes: A meta-analysis of prognosis and transplant outcomes
Abstract Background: TP53 mutations are among the most clinically significant genetic alterations in myelodysplastic syndromes (MDS), freque...
Psychosocial considerations during and after gene therapy for sickle cell disease: Building on consensus to guide comprehensive care
Abstract Introduction: The Cure Sickle Cell Initiative (CureSCi) Patient Readiness and Resilience Working Group (PRR) was formed in 2020 by...
Ex vivo drug sensitivity testing in Korean AML patients: Integration of functional and genomic profiles for predicting clinical response and survival
Abstract Acute myeloid leukemia (AML) is a genetically and phenotypically heterogeneous disease, with diverse therapeutic responses. Ex vivo...
The basis for the differential impact of BCOR and BCORL1 in aplastic anemia/paroxysmal nocturnal hemoglobinuria and myeloid neoplasia
Abstract BCOR and BCORL1 (BCOR/L1) are X-chromosomalTSGs affected by inactivating or hypomorphic somatic mutations (MT) in myeloid neoplasia...
Ultra high-risk multiple myeloma with early mortality despite quad-class and BCMA-directed therapies: Clinical and molecular insights
Abstract Intdocution: Multiple myeloma (MM) treatment has evolved significantly with the introduction of proteasome inhibitors (PIs), immuno...
Treosulfan – based conditioning in allogeneic hematopoietic stem-cell transplantation for lymphoid malignancies: Long term follows up.
Abstract Introduction: Treosulfan was recently approved by the FDA for the use in the conditioning regimen for allogenei...
Comparative efficacy and safety of FDA-approved prophylactic treatments for hereditary angioedema, including garadacimab, haegarda, lanadelumab, and berotralstat: A network meta-analysis
Abstract Introduction: Hereditary Angioedema (HAE) is a rare genetic disorder characterized by recurrent and potentially life-threatening ep...